Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Jadwiga Wedzicha; Donald Banerji; Kenneth Chapman; Jorgen Vestbo; Nicolas Roche; R Timothy Ayers; Chau Thach; Robert Fogel; Francesco Patalano; Claus Vogelmeier; Arnaud Bourdin

doi:10.1056/NEJMoa1516385

Back

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Journal article

Open access

Peer reviewed

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Jadwiga Wedzicha, Donald Banerji, Kenneth Chapman, Jorgen Vestbo, Nicolas Roche, R Timothy Ayers, Chau Thach, Robert Fogel, Francesco Patalano, Claus Vogelmeier, …

New England Journal of Medicine, Vol.374(23), pp.2222 - 2234

09/06/2016

DOI: https://doi.org/10.1056/NEJMoa1516385

PMID: 27181606

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1056/NEJMoa1516385View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
Creators - without role: Jadwiga Wedzicha - Novartis
Donald Banerji - Université Paris Cité
Kenneth Chapman - Novartis
Jorgen Vestbo
Nicolas Roche - Université Paris Cité
R Timothy Ayers - Université Paris Cité
Chau Thach - Université Paris Cité
Robert Fogel - Université Paris Cité
Francesco Patalano - Université Paris Cité
Claus Vogelmeier - Novartis
Arnaud Bourdin - Université de Montpellier, Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Publication Details: New England Journal of Medicine, Vol.374(23), pp.2222 - 2234
Identifiers: 9945607109311
Academic Unit: Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Language: English
Resource Type: Journal article
Local Fields: hal-01872709